Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 15 |
| Active Pipeline (Recruiting Now) | 4 (4) |
| Completed vs Stopped Early | 11 / 0 (0.0%) |
| Median Closed Actual Enrollment | 150 participants |
| Physical Hospital Site Disclosure | 60.4% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| University of Pennsylvania Abramson Cancer Center | Philadelphia, PA | 2 |
| Eye Research Foundation | Newport Beach, CA | 2 |
Explore interactive annual charts and M&A subsidiary rollups in the Opus Genetics Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.